13Apr

North East Innovation Lab receives investment of £1.4m to continue vital work to protect health

The North East Innovation Lab, originally established as part of the region’s integrated Covid hub, has received an investment of £1.4 million to continue work on assessing and evaluating the next generation of diagnostic tests.

 

Part of Newcastle Hospitals, the lab is based in the Newcastle Helix life sciences quarter, and supports the development of the cutting-edge technology needed to detect viruses and other health threats. 

The lab’s team of NHS scientists specialise in molecular biology, methodology and clinical research, with a client base including UK and international organisations, from university spin-outs to large multi-national corporations.

 

The new funding recognises the successful contribution the North East Innovation Lab has already made to evaluating new Covid-19 testing technologies. 

 

Since launching in January 2021, the team has been in contact with over 70 organisations across the globe, from the UK to the USA and Australia, and has 36 projects in place with 17 companies.

 

Dr John Tyson, head of the North East Innovation Lab, said: “We are delighted to secure this £1.4 investment, which allows us to continue our work to ‘test the tests’, helping developers to ensure their products perform well and accurately.

 

“Since we launched, many of our projects have involved working to detect and contain Covid-19, playing a role in tackling the pandemic and developing new diagnostic technologies across the world.

 

“Work has now expanded beyond this, and we are proud to be playing a key part in the advancement of the some of the most innovative diagnostics under development to protect against future virus and health threats.

 

“We manage a significant ‘biobank’, which contains thousands of biological samples essential for ‘testing the tests’. These include Covid-19, blood, serum and saliva and we can also collect specific samples to fit with the needs of clients.”

 

The £1.4 million investment in the lab’s future has come from the Academic Health Sciences Network North East and North Cumbria and NHS England’s Accelerated Access Collaborative.

Nicola Hutchinson, CEO of the Academic Health Science Network for the North East and North Cumbria, commented:

 

“We are delighted to work in collaboration with Newcastle Hospitals and regional partners, to support the ongoing success of the North East Innovation Lab.

 

“The lab is fundamental to the evaluation and subsequently the accelerated adoption of innovations which will support economic growth and improve patient and population health, whilst supporting the reduction of health inequalities.”

ENDS

About the North East Innovation Lab, part of Newcastle Hospitals

The North East Innovation Lab is part of Newcastle Hospitals and works with organisations to support the development of next generation diagnostics, through providing robust and independent performance testing.

This provides necessary evidence to move new technologies to the next stage of their development or to launch for mainstream use. 

 

Find out more at: https://commercial.newcastle-hospitals.nhs.uk/our-services/innovation-lab/

Related

EKF POC HbA1c analyzer demonstrates excellent performance in international evaluation study

Quo-Lab meets strict international quality targets – confirming it fit for purpose for diabetes tes...

Read More >

BBI Solutions & Dr C. Sturgeon consider International Standards for Cancer Biomarkers

Dr Catharine Sturgeon will be presenting her case for an international effort to align manufacturer’...

Read More >

Invasive Aspergillosis Screening in COVID-19 & Critical Care Patients

IMMY sõna Aspergillus Galactomannan Lateral Flow Assay recommended by the European Confederation of ...

Read More >

New Advanced Pipetting Academy Makes You a Pipetting Master

For many years Alpha Laboratories and Sartorius have delivered a popular training programme covering...

Read More >

In Brief This Week: VolitionRx, Bio-Techne, Biocept, Meridian Bioscience, and More

NEW YORK (360Dx) – VolitionRx reported a second quarter net loss of $3.5 million, or $.13 per share...

Read More >

PrimeStore® MTM novel viral transport media successfully evaluated by Public Health England for SARS-CoV-2 inactivation

Patented transport media manufactured by EKF Diagnostics can help to increase COVID-19 testing cap...

Read More >